David O'Neill

Title: David O'Neill: Innovator in Melanoma Research

Introduction

David O'Neill is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of melanoma research, particularly in the area of predicting survival outcomes for patients with metastatic melanoma. His innovative work has the potential to improve treatment strategies and patient care.

Latest Patents

David O'Neill holds a patent titled "Methods for predicting survival in metastatic melanoma patients." This patent describes cellular and genetic signatures that can be used to subcategorize stage III melanoma tumors. The methods outlined in the patent are particularly useful for establishing distinct criteria to differentiate between stage IIIB and IIIC melanoma patients. By assessing the cellular and genetic signatures of melanoma samples, healthcare providers can predict differential survival duration and sensitivity to various cancer therapies for these patients. The patent emphasizes the importance of gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions.

Career Highlights

David O'Neill is affiliated with New York University, where he conducts his research and develops innovative solutions for melanoma treatment. His work has garnered attention for its potential to enhance the understanding of melanoma biology and improve patient outcomes.

Collaborations

David collaborates with esteemed colleagues such as Dusan Bogunovic and Nina Bhardwaj. Their combined expertise contributes to advancing research in melanoma and cancer therapies.

Conclusion

David O'Neill's contributions to melanoma research through his innovative patent demonstrate his commitment to improving patient care and treatment outcomes. His work is a testament to the importance of research in the fight against cancer.